Altimmune (ALT) director receives grant of 48,800 stock options

Rhea-AI Filing Summary

Altimmune director Mitchel Sayare reported receiving a grant of 48,800 stock options to buy Altimmune common stock. The options have an exercise price of $2.82 per share and expire on May 1, 2036. They were awarded under the company’s non-employee director compensation policy and vest in substantially equal monthly installments over the 12 months following May 1, 2026, contingent on continued board service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SAYARE MITCHEL

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (option to buy)	48,800	$0.00	--

Holdings After Transaction: Stock Options (option to buy) — 48,800 shares (Direct, null)

Footnotes (1)

1. The options were granted pursuant to the Company's non-employee director compensation policy. The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date.

Key Figures

Stock options granted: 48,800 options Exercise price: $2.82 per share Expiration date: May 1, 2036

3 metrics

Stock options granted 48,800 options Grant to director Mitchel Sayare

Exercise price $2.82 per share Strike price for the stock options

Expiration date May 1, 2036 Option term end date

Key Terms

Stock Options (option to buy), non-employee director compensation policy, vested and exercisable

3 terms

Stock Options (option to buy) financial

"security_title: "Stock Options (option to buy)""

non-employee director compensation policy financial

"The options were granted pursuant to the Company's non-employee director compensation policy."

vested and exercisable financial

"The shares underlying the option become vested and exercisable in substantially equal monthly installments"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SAYARE MITCHEL

(Last) (First) (Middle)

910 CLOPPER ROAD

SUITE 201S

(Street)

GAITHERSBURG MARYLAND 20878

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Altimmune, Inc. [ ALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (option to buy)(1)	$2.82	05/01/2026		A		48,800		(2)	05/01/2036	Common Stock, par value $0.0001	48,800	$0	48,800	D

Explanation of Responses:

1. The options were granted pursuant to the Company's non-employee director compensation policy.

2. The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date.

	/s/ Gregory Weaver, as Attorney-in-Fact	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Altimmune (ALT) director Mitchel Sayare report in this Form 4 filing?

Mitchel Sayare reported receiving a grant of 48,800 stock options to buy Altimmune common stock. The options were issued as compensation for board service under Altimmune’s non-employee director compensation policy, rather than as an open-market purchase of existing shares.

What are the key terms of the 48,800 Altimmune (ALT) stock options granted?

The grant covers 48,800 stock options with an exercise price of $2.82 per share and an expiration date of May 1, 2036. Each option represents the right to buy one share of Altimmune common stock at that fixed exercise price in the future.

How do Mitchel Sayare’s Altimmune (ALT) stock options vest over time?

The options vest and become exercisable in substantially equal monthly installments over the 12 months following May 1, 2026. Vesting is conditioned on Sayare’s continued service as a non-employee director through each applicable monthly vesting date during that one-year period.

Is this Altimmune (ALT) Form 4 an open-market stock purchase or a compensation grant?

This Form 4 reflects a compensation-related stock option grant, not an open-market purchase. The options were granted at no upfront cost under Altimmune’s non-employee director compensation policy, with value realized only if the stock trades above the $2.82 exercise price.

What does the $2.82 exercise price mean for the Altimmune (ALT) option grant?

The $2.82 exercise price is the fixed amount Sayare must pay per share to exercise the options once vested. Economic benefit arises only if Altimmune’s market price exceeds $2.82, allowing potential gain on the difference between market price and exercise price.